Evidence map›Paper›PMID 36546649›Full record

ArticleAnnals of neurology2023

Experimental Neurotherapeutics: Surfing the Tidal Wave of New Opportunities.

Lauren B Reoma, Ania Busza, M Maral Mouradian, Petra Kaufmann, Erika F Augustine, Samuel Frank, Thomas P Sutula, Andrew J Cole, Heather D Fitter, William Meurer and 2 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of neurology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 10 institutions in 1 country.

Lauren B ReomaClinical Trials Unit, Office of the Clinical Director, National Institute of Neurological Disorders and Stroke, Bethesda, MD, USA.ORCID 0000-0001-6305-7723
Ania BuszaUniversity of Rochester School of Medicine and Dentistry, Department of Medicine, Rochester Regional Health; Department of Medicine, Division of Allergy, Immunology, and Rheumatology, Rochester, NY, USA.
M Maral MouradianRWJMS Institute for Neurological Therapeutics and Department of Neurology, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.
Petra KaufmannAffinia Therapeutics, Bannockburn, MA, USA.
Erika F AugustineKennedy Krieger Institute, Baltimore, MD, USA.ORCID 0000-0001-7257-8985
Samuel FrankDepartment of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Thomas P SutulaDepartment of Neurology, University of Wisconsin, Madison, WI, USA.
Andrew J ColeDepartment of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-0828-826X
Heather D FitterDivision of Neurology II, Office of Neuroscience, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.
William MeurerDepartment of Emergency Medicine, University of Michigan, Ann Arbor, MI, USA.
Avindra NathClinical Trials Unit, Office of the Clinical Director, National Institute of Neurological Disorders and Stroke, Bethesda, MD, USA.ORCID 0000-0003-0927-5855
Robert C GriggsUniversity of Rochester School of Medicine and Dentistry, Department of Medicine, Rochester Regional Health; Department of Medicine, Division of Allergy, Immunology, and Rheumatology, Rochester, NY, USA.
National Institute of Neurological Disorders and Stroke · USUniversity of Rochester Medical Center · USBaxalta (United States) · USBeth Israel Deaconess Medical Center · USCenter for Drug Evaluation and Research · USHarvard University · USKennedy Krieger Institute · USRutgers, The State University of New Jersey · USUniversity of Michigan · USUniversity of Wisconsin–Madison · US

Funding

Neuropathogenesis of Retroviral InfectionsZIANS003130 · NINDS · NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE · PI NATH, AVINDRA · 2011 to 2025
$73.7M
Meaningful Outcomes and Multi-Site Readiness for Clinical Trials in Juvenile Neuronal Ceroid LipofuscinosisU01NS101946 · NINDS · UNIVERSITY OF ROCHESTER · PI AUGUSTINE, ERIKA · 2019 to 2024
$3.7M
Intramural NIH HHS Z99 NS999999NINDS NIH HHS U01 NS101946
6 · The paper itself

Abstract

The subspecialty of experimental neurotherapeutics trains neurologists in discovering and developing new treatments for neurologic diseases. Based on development of exciting new treatments for genetic and inflammatory diseases, we predict that there will be many other breakthroughs. The job market has expanded rapidly in academia, the pharmaceutical industry, government, and not-for-profit sectors; many new opportunities can be anticipated. The burgeoning opportunities in the field mandate that training address the challenges of overcoming obstacles in therapeutic discovery, implementation science, and development of affordable and equitably available treatments. ANN NEUROL 2023;93:427-430.

Indexed as

Drug IndustryTidal WavesHumans

Identifiers

PMID36546649
PMCPMC9975021
OpenAlexW4312094812

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.